Skip to main content

MS news

Our news web pages include ground-breaking multiple sclerosis news and research from around the world. 

These news stories are taken from external sources and as such, MS-UK does not verify, endorse or accept responsibility for their content.

Some of these pages have been written for medical professionals and this can be reflected in the complexity of language and content.

Supporting you

We’re here to support you, whether you are awaiting a diagnosis of multiple sclerosis or have been living with the condition for years. 

Find out more about the MS-UK Helpline

Find out more about our Choices booklets

Find out more about New Pathways magazine

 


Researchers have developed an antibody with potential therapeutic effects that could help in the treatment of multiple sclerosis. Inserm Unit U919, directed by Prof. Denis Vivien ("Serine Proteases...
Merck, a leading science and technology company, today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) of the investigational...
A team of scientists led by University of Virginia researchers say they have found a connection between a molecule found in the body’s immune system and social behaviour. Working out of Jonathan...
A study published by researchers from Bristol University claims to show the immune system can be taught to stop treating harmless everyday proteins as if they were dangerous invasive diseases. By...
Symptoms of multiple sclerosis have long been linked with the body’s immune system, and immune response has also been linked to depression. Now researchers think it could be a shared pathological...
A comprehensive review article examining the role of gut bacteria and the viruses that infect them in the development and progression of MS, published in Journal of Interferon & Cytokine Research...
The European Commission (EC) has approved Zinbryta for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). Zinbryta, which is being developed by Biogen and AbbVie, is a...
Individuals with genetically increased body mass indexes are at a greater risk for developing multiple sclerosis (MS), according to analyses performed on two genome-wide association datasets. For...
Roche has announced that the European Medicines Agency (EMA) has validated the company’s Marketing Authorisation Application (MAA) of ocrelizumab for the treatment of relapsing multiple sclerosis (...
The multiple sclerosis drug Gilenya may help patients by directly enhancing nerve regeneration and increasing myelination in a way that is partly independent of its anti-inflammatory properties....

Pages